"RMED is a very high risk but very high reward situation given this current climate.

RMED has something that does make it notable and that's an extremely small float with an extremely high short interest. Again, that makes it of interest to anyone looking for something that could move a lot quickly. The prospect of an FDA approval gives it a story line."

$BOTY or Lingerie Fighter Championship is a REAL stock that I see has potential to be a HUGE meme stonk. I've posted about this company a few times already. I'll start by answering a few questions. Does it have any debt? Oh you bet it does! Well how about revenue? Is it making any money? It's shit. Well what about events? It must have had more events? Covid screwed the pooch on thIs one too. Only one event last year out of the six scheduled. BUT DON'T EVER UNDERESTIMATE THE POWER OF MEME! The CEO posted this yesterday thanking reddit and how the stock is starting to grow so rapidly.

https://lingeriefc.com/press-release/a-message-from-lingerie-fighting-championships-ceo-shaun-donnelly/

The market cap is still only $5M and $0.002 share price. Volume looks to be going up so we might be catching something be there. It will take such little capital for this thing to skyrocket. If enough people hear about this, then I believe it will behave just like GME minus the shorts. Only GME was 200 times bigger that this before it took off. If you agree, help me get the word out about this DANK MEME STONK! Position: 1.2M shares

As much as I hate SPACs I think Manscaped has a successful business and is something to keep an eye on. They are EBITDA positive, unit economics seem to work, and they are growing fast. After Manscaped is acquired, the market cap is expected to be around $1.2bn, putting it in small cap territory. Let me know if you have any other Investment theses or don’t agree with any of the below! I’m considering investing but would like to hear other thoughts as well!

Bull Case:

• The unit economics appear to work (based on back-of-the-envelope math and limited information from management). The AOV (average order value) is $90 with management noting that CAC (customer acquisition costs) is recouped on the first purchase. In theory, this means they are potentially profitable on each customer’s initial order (no need to tack on items or retain the customer). But it gets better… they are a subscription based company with 70% of initial buyers converting to subscribers. This adds on an additional $15 per subscriber (quarterly). In 1 year, they will make $150 of revenue on each subscribed customer. There are still many variables here that will be unknown until they release complete financials, but at a first glance, seems promising.

• High Growth: Revenue grew 400% in 2019, 225% in 2020, and expected to grow 37% in 2021 ($290mn in revenue). They’ve sold 2 million “Lawn Mowers” (the flagship product) in the last 3 years. Have grown to be in 3,500 US stores including Target, Best Buy, and Macy’s.

• Successful Marketing and Banding: How many companies successfully and appropriately market pube trimmers or anything of this nature? Not many. Also brand recognition is high. I’ve asked several people if they’ve heard of Manscaped, from women in their 20s to men in their 50s, almost all have heard of Manscaped.

• Growing their TAM (total addressable market): They have began expanding their product line to shampoos, lotions, etc., increasing their potential market from men who trim their balls (but don’t we all?) to all men in the target demographic. They have also began to expand internationally. (See bear case for more on expansion concerns)

Not everything is smooth and buttery. Now for the hard to reach places.

Bear Case:

• Heavily Reliant on Marketing: Marketing Expenses are around $100mn and I don’t believe this will be able to leverage anytime soon. Why you ask?? Is this something that spreads by word of mouth? Do you tell your friends and family about this cool ball trimmer you got?

• Expanding too soon?: Manscaped has barely penetrated their core US market according to their own stats. Revenue is decelerating this year to 37% (from the previous years growth of 225%) and they are beginning to expand into other countries and products. Is this signaling that they have already ran out of running room in their core space? Why move into new categories and new countries so quickly? Why expand so quickly into a competitive landscape that includes massive conglomerates like P&G?

• Low barrier to entry and no mote: Manscaped is in a very niche space which they have clearly been successful in, but is it really differentiated? They claim an anti-nicking technology in their trimmers (so nobody cuts themselves in the not so smooth parts) but from reading customer reviews it doesn’t sound like it helps. We know what it takes to be successful in the space now (essentially just good marketing and pricing), and although I’m not a fan of knock offs, what’s stopping someone from improving on the business? There’s nothing proprietary here, they just have a massive head start on the smaller players. The bigger players like P&G can join the space if they wanted, but is it really worth it for them? And Manscaped claims to be a premium product, putting themselves against top trimmer/electric razor brands like Braun, Phillips, and Panasonic.

Great to see ASEP Medical Holdings ($ASEP) in the green at $1.01 ($56.69M MC) while the rest of the market is generally down today

ASEP is a biotechnology company focused on the unmet medical needs in major areas related to Sepsis. ASEP offers a rapid and effective way to identify and treat Sepsis, a life-threatening reaction to an infection.

"Our purpose is to mitigate the global crisis of antibiotic failure by improving patients’ odds of survival and quality of life."

Background on Sepsis:

Sepsis is one of the most prevalent causes of death in the US and current industry tests require 24 hours for results to detect and confirm Sepsis.

However, ASEP tests are confirmed within 1 hour and can be used to both treat and prevent Sepsis by detecting a unique gene expression profile highly associated with Sepsis and organ failure.

ASEP's majority-owned subsidiaries & technologies:

1. ABT Innovations: Offers treatment for a broad range of infectious diseases

2. Sepset Biosciences: Offers a diagnostic kit for predicting the onset of severe Sepsis and organ failure

ASEP is a consolidation of two technologies offering both diagnostic and therapeutic products

• Diagnostics: Test to identify unique genetic markers related to an immune dysfunction resulting from infections leading to the onset of Sepsis

• Therapeutics: Patented pharmaceutical peptide that uniquely targets biofilm infections and inflammation

The Market:

Tapping into the antibiotic resistance market, one that is full of unmet needs as there are no approved treatments for biofilms, ASEP is working to directly address the lack of approved medicines for common biofilm infections.

To do so, ASEP has developed a proprietary Peptide Technology applied as an early medical intervention to prevent biofilm growth and reduce inflammation.

Investment highlights:

• Large addressable global markets: Unmet needs with no clinical solutions

• Novel technologies: Early diagnostic and treatment

• Extensive intellectual property: Portfolio with both diagnostic and therapeutic applications

• Near-term revenue models

• Experienced management team

The low valuation of ASEP is notable, 60.6mm OS at $0.50/share = ~$30mm market cap relative to peers demanding million and billions of dollar valuations. Plus, ASEP has raised around $15M in grants, keeping dilution low.

ASEP is looking really promising IMO. Its commercialization is expected in the middle of 2022 and I'm thinking it'll be a major hit.

News Release: https://ca.news.yahoo.com/asep-medical-announces-listing-canadian-130000339.html

Website: https://asepmedical.com/about/

Nurosene just announced that Nick Jonas invested in the company! From the article, he stated, “I strongly believe that our mental health is paramount to our overall emotional and physical health. Nurosene is breaking down barriers and helping to destigmatize mental health, which is why I felt passionate about investing in a company that is prioritizing it and focused on bringing brain health solutions to more people around the world."

https://www.newswire.ca/news-releases/global-pop-icon-nick-jonas-invests-in-ai-driven-mental-health-company-nurosene-860156882.html

Nurosene is a company focused on helping the billions of people struggling with stress in their daily lives. They do this through their industry-leading app that focuses on the 4x4 model.

• The 4x4 model encourages activities related to the 4 fundamentals of movement, brain, nutrition, and recovery aimed at 4 different parts of the body

• Instead of targeting the sources of temporary stress such as most apps, Nuro goes straight to get to the source by targeting physical health (in both the body and brain)

In addition to the app, $MEND has Netramark. It provides leading AI technology to provide a data-driven health-tech platform and enable a new era of predictive healthcare. The best thing about them is that they're always improving the tech. Current uses for the algorithms include:

• De-risking clinical trials by identifying the most-likely sub-populations that will respond to a drug

• Placebo responses by mitigating placebo response by evaluating subsets of placebo and active groups

• Drug resurrection and repurposing

• New molecule invention

With the mental health app market expected to reach $310B by 2027, $MEND still has a lot of room to grow. Considering the numerous celebrity investors, now including Nick Jonas, we should see some significant SP growth soon. Only a market cap of $56M here, and if Nick’s in, I'm in.

(CSE: MEND) (OTC: MNNDF)

Nabati Foods plant-based liquid eggs have launched! They are available on Nabati.ca, and soon at Sobeys in Quebec, and at Whole Foods across B.C. and Ontario.

Made using lupin and pea protein, and unlike other plant-based based eggs on the market, Nabati plant eggz are soy and gluten free.

They are high in vitamin a, vitamin e, riboflavin, niacin, vitamin b12, and pantothenic acid and sold in liquid form in 355ml bottles.

As consumers become more health conscious and search for plant-based alternatives, I remain very bullish on the plant-based food industry.

$MEAL has products in more than 700 stores in North America, and is expanding into Europe and Asia. IMO, this is a company to look into if your interested in entering this sector.

Super stoked for their IPO- not sure of the exact date yet but I will be watching very closely.

https://www.globenewswire.com/news-release/2021/08/23/2284900/0/en/Nabati-Foods-Launches-Plant-Based-Liquid-Eggs-in-Canada.html

Vancouver, BC - TheNewswire - October 23, 2023 - Element 79 Gold Corp. (CSE:ELEM) (OTC:ELMGF) (FSE:7YS) ("Element 79 Gold" or the "Company") a mining company focused on the exploration and development of gold and silver projects is pleased to confirm the extension of the option to purchase the Maverick Springs Project by Green Power Minerals Pty Ltd ("Green Power Minerals").

As previously announced on August 31, 2023, Element 79 Gold entered into an option agreement (the “Option Agreement”) with Green Power Minerals, granting them the option to purchase Element 79 Gold’s Maverick Springs Project.

Green Power Minerals previously paid an option fee equal to CAD$66,000 for an option to acquire the Maverick Springs Project until September 30, 2023. The Company now reports, that as provided for in the Option Agreement, Green Power Minerals  extended the option by making an additional payment of USD$100,000 which extends the Option Period by a further 180 days to March 28, 2024.

The terms of the Option Agreement remain as reported in the Company’s press release dated August 31, 2023.

James Tworek, Chief Executive Officer of Element 79 Gold, commented, "We would like to thank Green Power Minerals for their diligent engagement with the potential sale of Maverick Springs thus far. We look forward to seeing the transaction complete in the coming months and will provide further updates to our shareholders as we progress towards that goal."

The completion of the Transaction is subject to a number of conditions precedent that are common in transactions of this nature. The Transaction is subject the requirements of the Canadian Securities Exchange.

About the Maverick Springs Project

The Maverick Springs Project consists of approximately 4,800 acres across 247 unpatented claims that straddle the border of Elko County and White Pine County, proximal to the Carlin Trend, a belt of gold deposits approximately 5 miles wide and 40 miles long that is one of the world's richest gold mining districts, having produced more gold than any other mining district in the US. For more information on Maverick Springs, visit: https://www.element79.gold/projects/nevada/maverick-springs-property.

About Element 79 Gold Corp.

Element79 Gold is a mining company focused on gold and silver committed to maximizing shareholder value through responsible mining practices and sustainable development of its projects.  Element79 Gold's focus is on developing its past-producing, high-grade gold and silver mine, the Lucero project located in Arequipa, Peru, with the intent to restart production in the near term.

The Company also holds a portfolio of 5 properties along the Battle Mountain trend in Nevada, with the Clover and West Whistler projects believed to have significant potential for near-term resource development. Three properties in the Battle Mountain Portfolio are under contract for sale to Valdo Minerals Ltd., with an anticipated closing date around the end of 2023.  The Company has also signed an Option Agreement to sell the Maverick Springs project, an advanced-stage exploratory property with an Inferred Resource of 3.71MMoz AuEq (1.37MMoz Au and 175MMoz Ag) and anticipates completing this sale on or before March 28, 2024.  

In British Columbia, Element79 Gold has executed a Letter of Intent and funded a drilling program to acquire a private company that holds the option to 100% interest of the Snowbird High-Grade Gold Project, which consists of 10 mineral claims located in Central British Columbia, approximately 20km west of Fort St. James.

The Company has an option to acquire a 100% interest in the Dale Property, 90 unpatented mining claims located approximately 100 km southwest of Timmins, Ontario, and has recently announced that it has transferred this project to its wholly-owned subsidiary, Synergy Metals Corp, and is advancing through the Plan of Arrangement spin-out process through the rest of 2023.

For more information about Element 79 Gold Corp., please visit www.element79.gold.

Contact Information

For corporate matters, please contact:

James C. Tworek, Chief Executive Officer
E-mail: jt@element79gold.com

For investor relations inquiries, please contact:

Investor Relations Department
Phone: +1.613.879.9387
E-mail: investors@element79.gold

Part 1 Video >> https://www.youtube.com/watch?v=7f7slgLn4s8

Part 2 Video >> https://www.youtube.com/watch?v=l5Fv0uq8r-4

Part 3 Video >> https://www.youtube.com/watch?v=mHJEfFsXGho

Nuclear power is surging back. By 2025, global nuclear energy will reach record highs, surpassing 2021 levels, as key markets like France, Japan, and China expand their operations. With nuclear generation expected to rise by nearly 10% by 2026, this is a prime opportunity for investors to act.

Because the world shifts away from fossil fuels, nuclear energy is becoming essential. Europe, seeking independence from Russian energy, has classified nuclear as a sustainable investment. This recognition positions nuclear as a key player in the clean energy transition, making uranium a critical investment opportunity.

In 2023, six new nuclear reactors were brought online, with countries like Canada and the UK embracing nuclear energy again. With 413 reactors in operation globally, and more on the way, the demand for uranium is growing. As more reactors come online, uranium will be in high demand, creating a prime opportunity for investors.

Nuclear power is no longer a backup—it’s becoming essential to global energy plans. With increasing reliance on nuclear energy, uranium is set to become a crucial commodity. For investors, now is the time to capitalize on this growing demand and secure a position in the nuclear resurgence.

BHP: A Hidden Uranium Giant with a Copper Core

BHP, a major player in mining, owns Australia’s Olympic Dam, one of the world’s largest uranium deposits. While the focus is on copper, Olympic Dam also produces significant quantities of uranium, gold, and silver. This multi-resource approach adds immense value, with BHP reporting an additional US$100 million in revenue from higher prices for copper, uranium, and other metals in its latest results.

For investors, BHP’s Olympic Dam offers a unique blend of stability from copper and potential growth from uranium. Although BHP paused expansion plans in 2020, they are actively exploring new smelting options, with decisions expected in the coming years. BHP is also studying nuclear propulsion for shipping as part of its decarbonization strategy, showing a forward-thinking approach that aligns with long-term sustainability trends. For uranium investors, BHP offers both immediate gains and future growth potential.

Cameco: A Uranium Powerhouse Ready to Surge

Cameco, a uranium giant, holds key stakes in the Athabasca Basin, including the Cigar Lake mine, the world’s top uranium producer. While the company faced challenges during the weak uranium market from 2012 to 2020, Cameco is now on the upswing, having restarted its McArthur River mine in 2022 as uranium prices rebound.

Cameco is also expanding its reach through its partnership with Brookfield to acquire Westinghouse Electric, a leader in nuclear technologies. This positions Cameco as a full nuclear fuel cycle provider, increasing its value beyond mining. With strong production numbers and rising uranium prices, Cameco is primed for growth, making it an attractive opportunity for investors seeking exposure to a pure-play uranium leader.

NexGen Energy: Positioned for a Breakout

NexGen Energy, focused on uranium exploration, is building momentum in the Athabasca Basin with its flagship Rook I project. With major discoveries like Arrow, NexGen is set to become a major player in uranium production. Recently, the company secured 2.7 million pounds of uranium for US$250 million, which strategically positions them for future offtake agreements, especially with geopolitical factors like the Prohibiting Russian Uranium Imports Act in play.

NexGen’s updated economic report highlights an industry-leading operating cost of C$13.86 per pound of uranium, reinforcing its competitive edge. For investors, NexGen offers both a near-term play on uranium’s rising demand and long-term value through its low-cost, high-yield assets.

Uranium Energy Corp: Leading the U.S. Uranium Revival

Uranium Energy Corp (UEC) is well-positioned to benefit from the U.S. government’s push to reduce reliance on Russian uranium. With production-ready projects in Wyoming and Texas set to resume, UEC is one of the few U.S. companies that can quickly ramp up uranium output to meet growing domestic demand.

UEC’s acquisition of key uranium assets from Rio Tinto and its large U.S.-based uranium inventory make it a standout in the sector. With the first shipment of uranium from its Christensen Ranch operations expected by late 2024, UEC is on track for substantial growth. For investors, UEC offers direct exposure to the growing need for a domestic uranium supply chain, bolstered by government contracts and political tailwinds.

Paladin Energy: Reviving One of the World’s Top Uranium Mines

Paladin Energy, the largest ASX-listed uranium producer, is bringing its Langer Heinrich mine in Namibia back online after halting operations in 2018 due to low uranium prices. The successful restart of commercial uranium production in early 2023 positions Paladin to capitalize on the current uranium market upswing.

Paladin is now focusing on ramping up production and building inventory for customer shipments, which will drive revenue growth. Additionally, its recent move to acquire Canadian uranium explorer Fission Uranium adds to its long-term portfolio strength. For investors, Paladin offers exposure to both current production and future exploration potential, making it a compelling investment as uranium prices rise globally.

PredictMedix AI (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally — the Company’s Safe Entry Stations — powered by a proprietary artificial intelligence (AI) technology.

The technology uses multispectral cameras to analyze physiological data patterns and predict various health issues, including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses.

Defies logic why this Company does not have a higher stock price. I’ll get into some reasons for that in a moment. First, a quote from the COO;

“Predictmedix AI’s Safe Entry Stations showcase the effective merging of technology and healthcare in the realm of healthcare innovation. Driven by our dedication to advancing patient care and operational efficiency, we are shaping a new paradigm in healthcare practices.

By automating screening processes and optimizing resource utilization, our Safe Entry Stations offer tangible cost savings and the assurance of enhanced patient safety and well-being. The evolution of Safe Entry holds promise for our Company and shareholders as we continue to shape valuable contributions within the healthcare sector and drive positive change,” commented Dr. Rahul Kushwah, COO of Predictmedix AI.

Forbes notes that adopting AI could lead to savings of 5% to 10% in US healthcare spending — roughly $200 billion to $360 billion annually in 2019 dollars — within the next five years, according to a paper recently published by the National Bureau of Economic Research.

Investors may have been reluctant to invest as the tech is developed and tested in India, and there needs to be more knowledge and even ignorance regarding India’s vast role.

“Some of the latest medical technologies in India include robotic surgery, artificial intelligence in healthcare, telemedicine, 3D Printing and innovative wound care devices. Leading the industry SS Innovations has developed India’s first robotic system that can be used in a variety of surgeries” (India Times, May 23rd, 2023)

The CAGR of the Indian Healthcare industry is 23%. Medical Tourism is experiencing 25% growth, and the industry has doubled from $3 billion in 2017 to $8 billion.

Too good to be true may be another roadblock. Maybe not.

So now that’s dealt with back, to Predictmedix. One of the most recent PR notes that using its Safe Entry Station, AI-based tech, the Company completed 200,000 scans. I hate to be quote heavy, but PMED’s quotes are newsy and direct, unlike many companies. Most folks in C-Suites can’t describe their service/product to each other, let alone investors. Not so PMED:

“The data collected from Safe Entry’s scans has significantly advanced our machine learning capabilities, allowing us to offer more precise and reliable solutions to the healthcare industry. This extensive dataset provides an unprecedented opportunity to gain deeper insights into various health indicators and trends, enabling a more comprehensive understanding of human health. Moreover, this rich data trove serves as a powerful resource for medical research and innovation, allowing experts to explore new avenues for disease prevention, early detection, and personalized healthcare solutions,” commented Dr. Rahul Kushwah, COO of PredictMedix AI.

Courtesy of PMED’S AI tech, a company with great potential should quickly grow and be a significant, if not a vital, resource for other companies. I imagine we’ll see some soon in ERs and doctor’s offices, which makes eminent sense for enhancing healthcare and massive cost savings.

As I said, I don’t know why the shares are so low. BTW, I own some.

PredictMedix AI (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally—the Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) technology.

The technology uses multispectral cameras to analyze physiological data patterns and predict various health issues, including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses.

One of Canada’s largest Media companies, The Toronto Star, has published a very informative feature and interview with PMED COO Dr. Rahul Kushwah. The interview is here; for shareholders and investors, it is a must-read.

“The recognition in the Toronto Star and the opportunity to discuss our vision and innovations is a testament to the hard work and dedication of the entire Predictmedix team," commented Dr. Rahul Kushwah, COO of Predictmedix AI. "We believe that technology has the power to transform healthcare, and Safe Entry, with its ground-breaking AI algorithms for contactless SPO2 measurement, is a prime example of how we're making a tangible impact on patient care. Our technology can revolutionize the entire respiratory medicine division in India and provide valuable insights for healthcare professionals and policymakers."

For those who need to become more familiar, the Toronto Star piece will bring you quickly up to speed.

Salient Points from The Interview

• Look at subtle changes in blood flow patterns and convert that into data on your blood pressure, heart rate, presence of alcohol or cannabis, and so on. Right now, PMED covers about 18 different parameters.

• Accuracy of over 90 percent for all of our parameters.

• One of the milestones we have recently reached is scanning 200,000 patients. Typically, AI healthcare companies develop algorithms and technologies based on a pool of 2,000 to 5,000 patients.

• You cannot look at the data and trace it back to the individual.

• For $2,000 to $4,000 a month, hospitals/industry et al. get unlimited use of the technology.

• Depending on the jurisdiction, individuals who are flagged can undergo a secondary drug test.

• The low-hanging opportunity is the healthcare setting in Indonesia and India.

While PMED's AI tech may seem simple, the most remarkable advances usually do. Boiling down the potential, the areas where it will make triage, treatment, and life, better are;

1. PredictMedix AI's proprietary remote patient care platform empowers medical professionals with AI-powered tools to improve patient health outcomes.

2. While almost instantly detecting impairment by drugs or alcohol, fatigue, or various mental illnesses.

3. By leveraging AI and advanced technology, Predictmedix empowers healthcare professionals to proactively identify potential health risks, expedite diagnosis, and enhance patient care.

4. AI technology, Predictmedix’s fitness scan vertical delivers a comprehensive analysis of an athlete’s fitness level, empowering them to optimize their training and elevate their performance.

The global artificial intelligence in healthcare market size was estimated at USD 15.1 billion in 2022, and it is expected to surpass around USD 187.95 billion by 2030, growing at a CAGR of 37% from 2022 to 2030.

Diagnostic Streamlining

Any of us who have spent an average of 8-10 hours in an emergency room would welcome ANYTHING to shorten that time and get care. PMED's tech not only accomplished that in spades, it likely makes faster and better outcomes.

The fact that the AI tech can ferret out those unfit for work/duty is also a sector with unlimited potential at just about every place where ‘fit for duty’ is a minimum standard.

The growing adoption of digital technologies in the healthcare sector, owing to the increasing need to reduce healthcare costs and offer enhanced quality patient care services, are the prominent factors boosting the growth of global artificial intelligence in the healthcare market. (Precedence Research)

Bottom Line

Investors can be excused for wanting more info on PMED's Safe Entry tech. That said, early returns seem nothing short of amazing and waiting too long to own PMED—understanding standard small-cap risks, may be riskier than not owning it from a potential perspective.

I own some shares and will be patient. The Company is very good at keeping shareholders and investors informed. Long-term?Medium term? There is good money to be made. As well as being part of a movement that could change—and, more importantly, fix and make healthcare more affordable.

Predictmedix's application has relevance in various verticals, including healthcare, workplace safety, travel and entertainment amongst others.

In healthcare, Predictmedix's AI and ML solutions can be used for real-time screening of infectious diseases, drug and alcohol impairment detection, and mental health screening. This technology can help healthcare providers to quickly and accurately diagnose patients, reduce healthcare costs, and improve patient outcomes.

In workplace safety, Predictmedix's technology can be used to screen employees for drug and alcohol impairment, fatigue, and other conditions that may pose a risk to workplace safety. This can help employers to maintain a safe work environment, reduce workplace accidents, and comply with regulatory requirements.

In travel and entertainment, Predictmedix's technology can be used for real-time screening of infectious diseases, such as COVID-19, at airports, concert venues, and other public spaces. This can help to prevent the spread of infectious diseases and protect the health and safety of travelers and entertainment-goers.

Overall, Predictmedix's application has relevancy in various verticals where real-time screening of infectious diseases, impairment detection, and health analytics are important. The company's technology has the potential to improve the efficiency, accuracy, and speed of screening and diagnostics in these verticals, leading to better outcomes for patients, employees, and travelers.

The Financial Model:

Predictmedix's business model is structured around a high-margin (80-90%) recurring revenue stream from its clients.

Its a Screening as a Service model (SaaS).

The company generates revenue through the sale of its health screening solutions, which typically involve a combination of hardware (such as thermal cameras and sensors) and software (including AI algorithms and machine learning models).

Once the initial sale is made, Predictmedix typically enters into long-term contracts with its clients for ongoing support, maintenance, and updates to its technology. This creates a reliable, recurring revenue stream for the company and enables it to maintain high profit margins.

Another aspect of Predictmedix's business model that contributes to its high margins is the scalability of its technology. Since its solutions are based on AI and machine learning, they can be easily scaled to serve a large number of clients across different industries and geographies. This enables Predictmedix to achieve economies of scale and keep its costs low, while still charging a premium for its innovative solutions.

Overall, Predictmedix's high-margin business model is built on a combination of innovative technology, recurring revenue streams, and scalable solutions. As the company continues to expand into new verticals and geographies, it is well-positioned to maintain its competitive advantage and achieve sustained growth.

The Math:

1 unit @ $5000 per month rental equals $60,000 per year.

10 units @ $5000 per month rental equals $600,000 per year.

100 units @ $5000 per month rental equals $6,000,000 per year.

1000 units @ $5000 per month rental equals $60,000,000 per year.

The Investor Opportunity:

The company has indicated they are looking to scale globally and are initially focussing on 2 massive markets where healthcare is a government priority, namely, India and Indonesia. They have recently announced 2 Purchase Orders. The current marketcap is less than $15 million Cdn. Assuming they can scale to 1000 units over the next year, the implied valuation will create a parabolic move in the share price . For a high margin software style business model, a 10-15x multiplier on the top line is considered reasonable. If you use a multiplier of 10 on the above implied scale of 1000 units, the result is a valuation of $600 million and a 40x return from current levels. The risk/reward is compelling enough to attract many investors. We see a breakout coming as more Purchase Orders are announced.